Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

OptimizeRx Corp Director's Dealing 2025

Dec 22, 2025

33090_dirs_2025-12-22_cf19e8a6-3295-459f-8022-358a2097d15c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OptimizeRx Corp (OPRX)
CIK: 0001448431
Period of Report: 2025-12-19

Reporting Person: Odence-Ford Marion (Chief Legal & Admin Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-12-19 Common Stock M 3928 Acquired 94526 Direct
2025-12-19 Common Stock F 1153 $13.51 Disposed 93373 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-12-19 Restricted Stock Units $ M 3928 Disposed 2026-12-19 Common Stock (3928) Direct

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: These shares were withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended.

F3: The restricted stock units vest in three equal annual installments beginning December 19, 2024, the first anniversary of the grant date.